ABOS
NASDAQ · Biotechnology
Acumen Pharmaceuticals Inc
$2.30
+0.06 (+2.68%)
Open$2.22
Previous Close$2.24
Day High$2.38
Day Low$2.19
52W High$3.60
52W Low$1.22
Volume—
Avg Volume472.4K
Market Cap161.63M
P/E Ratio—
EPS$-1.63
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+866.1% upside
Current
$2.30
$2.30
Target
$22.22
$22.22
$18.81
$22.22 avg
$35.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.13M | 32.40M | 26.28M |
| Net Income | 3.79M | 3.97M | 2.79M |
| Profit Margin | 11.8% | 12.2% | 10.6% |
| EBITDA | 5.50M | 6.39M | 4.32M |
| Free Cash Flow | 1.86M | 2.43M | 2.61M |
| Rev Growth | +20.9% | +8.5% | +2.1% |
| Debt/Equity | 0.36 | 0.35 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |